Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
Majem, M. Forster, M. D. Krebs, Matthew G Peguero, J. Clay, T. D. Felip, E. Iams, W. Roxburgh, P. de Speville, B. D. Bajaj, P.
Majem, M.
Forster, M. D.
Krebs, Matthew G
Peguero, J.
Clay, T. D.
Felip, E.
Iams, W.
Roxburgh, P.
de Speville, B. D.
Bajaj, P.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Majem M, Forster MD, Krebs MG, Peguero J, Clay TD, Felip E, et al. Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors. Journal of Thoracic Oncology. 2023 Apr;18(4):S43-S4. PubMed PMID: WOS:000995007600012.